'Well, if the booster is up to 2 times, 3 times, 4 times it's not crazy to make a profit. Indeed, he answered to the moon.'
Germany's Covid-19 vaccine maker BioNTech reported an encouraging surge in sales of anti-coronavirus injections it has worked on with US pharmaceutical company Pfizer.
According to the report, BioNTech recorded a net profit of €10.3 billion in 2021, up from the €15 billion recorded in 2020 when the pandemic began.
Following the company's Chief Executive Officer (CEO), Ugur Sahin, the development of a vaccine designed to fight the coronavirus has had a 'big impact' on human health and the global economy.
The fact that the company stated that it had distributed 2.6 billion doses of vaccine based on mRNA technology in 2021, subsequently generating a yield of €19 billion in the same year.
Also for 2022, BioNTech recommends vaccine yields selling for €13 billion to €17 billion and aims to channel €1.5 billion into research and company development plans.
For now, BioNTech is said to be working on a vaccine against the Omicron variant while the pharmaceutical company is also actively developing treatments for malaria, dry cough and other ailments.
BioNTech also said the proceeds would benefit the royal tube by the company making €4.8 billion in excise payments in 2021 alone.
In general, the rise of the small biotechnology company from Mainz, Germany has had an impact on the country's economy, with economists estimating it will account for 0.5% of all economic activity by 2021.
Meanwhile, BioNTech is said to be launching a €1.5 billion share buyback program over the next 2 years and paying a cash dividend of €2 a share.
